Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galecto, Inc. (GLTO : NSDQ)

• Company Description    Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters in Copenhagen, Denmark. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $7.32 Daily Weekly Monthly 20 Day Moving Average: 4,772,683 shares Shares Outstanding: 1.32 (millions) Market Capitalization: $9.70 (millions) Beta: 1.38 52 Week High: $18.45 52 Week Low: $2.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 85.32% 81.93% 12 Week 124.54% 108.12% Year To Date 57.42% 36.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 75 STATE STREET SUITE 100 - BOSTON,MA 02109 DNK ph: 45-7070-5210 fax: - None http://www.galecto.com

• General Corporate Information    Officers Hans T. Schambye - President; Chief Executive Officer and Director Carl Goldfischer - Chairman Lori Firmani - Interim Chief Financial Officer Jayson Dallas - Director Amit Munshi - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36322Q206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/07/25 Share - Related Items Shares Outstanding: 1.32 Most Recent Split Date: 8.00 (0.04:1) Beta: 1.38 Market Capitalization: $9.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-11.05 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.01 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 35.00% vs. Previous Quarter: -35.42% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -115.70 03/31/25 - -98.27 ROA 09/30/25 - - 06/30/25 - -95.42 03/31/25 - -84.29 Current Ratio 09/30/25 - - 06/30/25 - 4.96 03/31/25 - 9.62 Quick Ratio 09/30/25 - - 06/30/25 - 4.96 03/31/25 - 9.62 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 7.27 03/31/25 - 9.34 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©